Aisling Capital Management LP Verona Pharma PLC Transaction History
Aisling Capital Management LP
- $286 Million
- Q1 2025
A detailed history of Aisling Capital Management LP transactions in Verona Pharma PLC stock. As of the latest transaction made, Aisling Capital Management LP holds 615,352 shares of VRNA stock, worth $56.3 Million. This represents 13.66% of its overall portfolio holdings.
Number of Shares
615,352
Previous 1,115,352
44.83%
Holding current value
$56.3 Million
Previous $51.8 Million
24.57%
% of portfolio
13.66%
Previous 18.98%
Shares
4 transactions
Others Institutions Holding VRNA
# of Institutions
290Shares Held
74.3MCall Options Held
933KPut Options Held
1.98M-
Perceptive Advisors LLC New York, NY6.56MShares$601 Million17.44% of portfolio
-
Janus Henderson Group PLC London, X05.52MShares$505 Million0.2% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y93.92MShares$359 Million17.31% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.46MShares$316 Million13.82% of portfolio
-
Eventide Asset Management, LLC Boston, MA2.89MShares$265 Million3.9% of portfolio
About Verona Pharma plc
- Ticker VRNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,954,200
- Market Cap $5.58B
- Description
- Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...